

Thomas Reiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6137497/publications.pdf>

Version: 2024-02-01

141
papers

6,147
citations

57631

44
h-index

82410

72
g-index

157
all docs

157
docs citations

157
times ranked

7685
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes. <i>Inorganic Chemistry</i> , 2022, 61, 1456-1470.	1.9	8
2	Principles and Applications of Auger-Electron Radionuclide Therapy. , 2022, , .		0
3	Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation. <i>Scientific Reports</i> , 2022, 12, 6185.	1.6	14
4	PARP-1 expression in melanocytic lesions: towards PARPi-FL based molecular diagnosis of melanoma. , 2022, , .		0
5	Imaging Early-Stage Metastases Using an 18F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant. <i>Molecular Imaging and Biology</i> , 2021, 23, 340-349.	1.3	6
6	Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog. <i>Journal of Nuclear Medicine</i> , 2021, 62, 839-848.	2.8	7
7	[18F]PARPi Imaging Is Not Affected by HPV Status In Vitro. <i>Molecular Imaging</i> , 2021, 2021, 1-10.	0.7	2
8	Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers. <i>Molecular Pharmaceutics</i> , 2021, 18, 940-951.	2.3	3
9	A modular approach toward producing nanotherapeutics targeting the innate immune system. <i>Science Advances</i> , 2021, 7, .	4.7	20
10	REPLY TO LETTER TO THE EDITOR: POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.261950.	2.8	0
11	Auger: The future of precision medicine. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 50-53.	0.3	14
12	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3618-3630.	3.3	21
13	Pharmacological Inhibition of the Voltage-Gated Sodium Channel NaV1.7 Alleviates Chronic Visceral Pain in a Rodent Model of Irritable Bowel Syndrome. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1362-1378.	2.5	10
14	Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase. <i>Molecular Pharmaceutics</i> , 2021, 18, 2470-2481.	2.3	7
15	Rapid detection of SARS-CoV-2 using a radiolabeled antibody. <i>Nuclear Medicine and Biology</i> , 2021, 98-99, 69-75.	0.3	2
16	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. <i>Molecular Pharmaceutics</i> , 2021, 18, 3418-3428.	2.3	16
17	Combined PARP1-targeted nuclear contrast and reflectance contrast enhances confocal microscopic detection of basal cell carcinoma. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262600.	2.8	5
18	Combining PARPi-FL fluorescence and reflectance contrast for improved detection of basal cell carcinoma (BCC). , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹ Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. <i>Bioconjugate Chemistry</i> , 2020, 31, 360-368.	1.8	22
20	An ⁸⁹ Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. <i>Journal of Nuclear Medicine</i> , 2020, 61, 433-436.	2.8	25
21	Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 437-442.	2.8	11
22	TOPKi-NBD: a fluorescent small molecule for tumor imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1003-1010.	3.3	5
23	Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer. <i>Nuclear Medicine and Biology</i> , 2020, 80-81, 1-12.	0.3	12
24	Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 394-405.	0.4	48
25	Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa119.	0.4	14
26	Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor ⁶⁴ Cu-Macrin in Mice, Rabbits, and Pigs. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010586.	1.3	32
27	Oncology-Inspired Treatment Options for COVID-19. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1720-1723.	2.8	15
28	Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures.. <i>Journal of Nuclear Medicine</i> , 2020, 62, jnumed.120.253575.	2.8	3
29	Optical Imaging Modalities: Principles and Applications in Preclinical Research and Clinical Settings. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1419-1427.	2.8	49
30	Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 786-801.e19.	13.5	101
31	Leveraging synthetic chlorins for bio-imaging applications. <i>Chemical Communications</i> , 2020, 56, 12608-12611.	2.2	5
32	A one-pot radiosynthesis of [¹⁸ F]PARPi. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 419-425.	0.5	6
33	Tumor Targeting by α -v β 3-Integrin-Specific Lipid Nanoparticles Occurs <i>via</i> Phagocyte Hitchhiking. <i>ACS Nano</i> , 2020, 14, 7832-7846.	7.3	69
34	Improved radiosynthesis of ¹²³ I-MAPI, an auger theranostic agent. <i>International Journal of Radiation Biology</i> , 2020, , 1-7.	1.0	13
35	Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. <i>Nature Biomedical Engineering</i> , 2020, 4, 272-285.	11.6	43
36	High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies. <i>Nature Biomedical Engineering</i> , 2020, 4, 286-297.	11.6	92

#	ARTICLE	IF	CITATIONS
37	Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 170.	1.6	57
38	Fluorescence-guided resection of tumors in mouse models of oral cancer. <i>Scientific Reports</i> , 2020, 10, 11175.	1.6	15
39	Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging. <i>Nuclear Medicine and Biology</i> , 2020, 84-85, 80-87.	0.3	12
40	PET/CT Imaging with an 18F-Labeled Galactodendritic Unit in a Galectin-1-Overexpressing Orthotopic Bladder Cancer Model. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1369-1375.	2.8	4
41	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3110-3116.	3.2	36
42	Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging. <i>Nature Nanotechnology</i> , 2020, 15, 398-405.	15.6	42
43	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. <i>Clinical Cancer Research</i> , 2020, 26, 2871-2881.	3.2	69
44	Fluorescence labeling of a NaV1.7-targeted peptide for near-infrared nerve visualization. <i>EJNMMI Research</i> , 2020, 10, 49.	1.1	10
45	Smartphone epifluorescence microscopy for cellular imaging of fresh tissue in low-resource settings. <i>Biomedical Optics Express</i> , 2020, 11, 89.	1.5	19
46	Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	51
47	Fluorescence Imaging of Peripheral Nerves by a Na ^v 1.7-Targeted Inhibitor Cystine Knot Peptide. <i>Bioconjugate Chemistry</i> , 2019, 30, 2879-2888.	1.8	20
48	Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1743-1752.	0.5	14
49	Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. <i>Scientific Reports</i> , 2019, 9, 8550.	1.6	16
50	Blocking of Glucagonlike Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity for Î²-Cells in a Mouse Model of Type 1 Diabetes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1635-1641.	2.8	14
51	Novel latonduine derived proligands and their copper(II) complexes show cytotoxicity in the nanomolar range in human colon adenocarcinoma cells and <i>in vitro</i> cancer selectivity. <i>Dalton Transactions</i> , 2019, 48, 10464-10478.	1.6	17
52	Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. <i>Clinical Cancer Research</i> , 2019, 25, 4332-4342.	3.2	24
53	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2015-2026.	2.3	66
54	[18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model. <i>Molecular Imaging and Biology</i> , 2019, 21, 705-712.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Smartphone-based epifluorescence microscope for fresh tissue imaging. , 2019, , .		0
56	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering, 2018, 2, 279-292.	11.6	94
57	Bioorthogonal Masking of Circulating Antibodyâ€™TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjugate Chemistry, 2018, 29, 538-545.	1.8	35
58	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a HumanÂAntibody Detects ClinicallyÂRelevant Atherothrombosis. Journal of the American College of Cardiology, 2018, 71, 321-335.	1.2	39
59	Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nature Communications, 2018, 9, 176.	5.8	75
60	Reversible Electroporationâ€™Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With ⁸⁹ Zr-Labeled Reporter Nanoparticles. Molecular Imaging, 2018, 17, 153601211774972.	0.7	21
61	PARP-1â€™Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	2.8	51
62	Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib. Journal of Nuclear Medicine, 2018, 59, 1316-1320.	2.8	13
63	Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening. Molecular Imaging, 2018, 17, 153601211880864.	0.7	21
64	Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models. EJNMMI Research, 2018, 8, 59.	1.1	16
65	Leveraging PET to image folate receptor Î± therapy of an antibody-drug conjugate. EJNMMI Research, 2018, 8, 87.	1.1	12
66	Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. Immunity, 2018, 49, 819-828.e6.	6.6	161
67	Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. Bioconjugate Chemistry, 2018, 29, 3776-3782.	1.8	15
68	Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chemical Science, 2018, 9, 5646-5657.	3.7	25
69	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	2.8	36
70	Molecular Imaging and Molecular Imaging Technologies. , 2018, , 3-27.		0
71	Evaluation of [18 F]-ATRI as PET tracer for in vivo imaging of ATR in mouse models of brain cancer. Nuclear Medicine and Biology, 2017, 48, 9-15.	0.3	4
72	Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease. Nature Communications, 2017, 8, 14064.	5.8	118

#	ARTICLE	IF	CITATIONS
73	Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. <i>Cancer Research</i> , 2017, 77, 2112-2123.	0.4	27
74	Development of a New Folate-Derived Ga-68-Based PET Imaging Agent. <i>Molecular Imaging and Biology</i> , 2017, 19, 754-761.	1.3	19
75	Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. <i>ACS Nano</i> , 2017, 11, 5785-5799.	7.3	137
76	Imaging-guided revival of nanomedicine?. <i>Nanomedicine</i> , 2017, 12, 89-90.	1.7	3
77	Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging. <i>Bioconjugate Chemistry</i> , 2017, 28, 1413-1421.	1.8	13
78	Sonophore labeled RGD: a targeted contrast agent for optoacoustic imaging. <i>Photoacoustics</i> , 2017, 6, 1-8.	4.4	23
79	Integrating nanomedicine and imaging. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2017, 375, 20170110.	1.6	5
80	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7441-E7449.	3.3	28
81	A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	0
82	cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339. <i>Dalton Transactions</i> , 2017, 46, 11925-11941.	1.6	11
83	Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent. <i>Molecular Imaging</i> , 2017, 16, 153601211772378.	0.7	16
84	Specific Binding of Liposomal Nanoparticles through Inverse Electron-Demand Diels-Alder Click Chemistry. <i>ChemistryOpen</i> , 2017, 6, 615-619.	0.9	7
85	Synthesis of a Fluorescently Labeled ⁶⁸ Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 720-725.	1.3	30
86	A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. <i>Journal of Controlled Release</i> , 2017, 262, 47-57.	4.8	44
87	Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. <i>Nature Protocols</i> , 2017, 12, 1472-1497.	5.5	19
88	A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	5
89	Molecular Imaging of PARP. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1025-1030.	2.8	75
90	A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. <i>Theranostics</i> , 2016, 6, 2267-2277.	4.6	53

#	ARTICLE	IF	CITATIONS
91	Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0147752.	1.1	26
92	Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. Bioconjugate Chemistry, 2016, 27, 1789-1795.	1.8	60
93	Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nature Communications, 2016, 7, 11838.	5.8	94
94	Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Scientific Reports, 2016, 6, 21371.	1.6	58
95	Near-Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem, 2016, 11, 1978-1982.	1.6	5
96	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6731-E6740.	3.3	95
97	Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. Molecular Imaging and Biology, 2016, 18, 386-392.	1.3	70
98	In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	2.3	78
99	¹⁸ F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. Bioconjugate Chemistry, 2016, 27, 298-301.	1.8	127
100	Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰ Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Journal of Nuclear Medicine, 2015, 56, 805-811.	2.8	39
101	Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging. Journal of Visualized Experiments, 2015, , e52335.	0.2	6
102	Development of a clickable bimodal fluorescent/PET probe for in vivo imaging. EJNMMI Research, 2015, 5, 120.	1.1	27
103	PET Imaging of Tumor-Associated Macrophages with ⁸⁹ Zr-Labeled High-Density Lipoprotein Nanoparticles. Journal of Nuclear Medicine, 2015, 56, 1272-1277.	2.8	145
104	Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Molecular Imaging and Biology, 2015, 17, 848-855.	1.3	66
105	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	4.7	173
106	Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI Research, 2015, 5, 123.	1.1	48
107	Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. Molecular Pharmaceutics, 2015, 12, 3575-3587.	2.3	88
108	Effect of Small-Molecule Modification on Single-Cell Pharmacokinetics of PARP Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 986-995.	1.9	42

#	ARTICLE	IF	CITATIONS
109	Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. <i>ChemistryOpen</i> , 2014, 3, 48-53.	0.9	24
110	Synthesis of the first radiolabeled ¹⁸⁸ Re heterocyclic carbene complex and initial studies on its potential use in radiopharmaceutical applications. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 441-447.	0.5	11
111	The inverse electron demand Diels-Alder click reaction in radiochemistry. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 285-290.	0.5	53
112	Efficient Acid-Catalyzed ¹⁸ F/ ¹⁹ F Fluoride Exchange of BODIPY Dyes. <i>ChemMedChem</i> , 2014, 9, 1368-1373.	1.6	33
113	A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1706-1711.	2.8	85
114	In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent. <i>Bioconjugate Chemistry</i> , 2014, 25, 1323-1330.	1.8	47
115	PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging. <i>Neoplasia</i> , 2014, 16, 432-440.	2.3	52
116	Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. <i>Nature Communications</i> , 2013, 4, 1504.	5.8	172
117	Synthetic strategies for efficient conjugation of organometallic complexes with pendant protein reactive markers. <i>Journal of Organometallic Chemistry</i> , 2013, 744, 82-91.	0.8	9
118	¹⁸ F-Labeled-Bioorthogonal Liposomes for In Vivo Targeting. <i>Bioconjugate Chemistry</i> , 2013, 24, 1784-1789.	1.8	74
119	Targeting Cathepsin E in Pancreatic Cancer by a Small Molecule Allows In Vivo Detection. <i>Neoplasia</i> , 2013, 15, 684-IN3.	2.3	36
120	Phenylalanine as a biogenic ligand with flexible η^6 - and $\eta^6:\eta^1$ -coordination at ruthenium(ii) centres. <i>Dalton Transactions</i> , 2013, 42, 8692.	1.6	13
121	Metal-Conjugated Affinity Labels: A New Concept to Create Enantioselective Artificial Metalloenzymes. <i>ChemistryOpen</i> , 2013, 2, 50-54.	0.9	22
122	A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1389-1396.	2.8	247
123	Metal-Conjugated Affinity Labels: A New Concept to Create Enantioselective Artificial Metalloenzymes. <i>ChemistryOpen</i> , 2013, 2, 40-40.	0.9	0
124	Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications. <i>Journal of Visualized Experiments</i> , 2013, , e50772.	0.2	0
125	Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents. <i>Neoplasia</i> , 2012, 14, 169-IN3.	2.3	97
126	Efficient ¹⁸ F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta Cells. <i>ChemistryOpen</i> , 2012, 1, 177-183.	0.9	38

#	ARTICLE	IF	CITATIONS
127	Microfluidic Cell Sorter (μ FCS) for On-chip Capture and Analysis of Single Cells. <i>Advanced Healthcare Materials</i> , 2012, 1, 432-436.	3.9	43
128	Bioorthogonal Imaging of Aurora Kinase A in Live Cells. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 6598-6603.	7.2	85
129	In Vivo PET Imaging of Histone Deacetylases by 18 F-Suberoylanilide Hydroxamic Acid (18 F-SAHA). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5576-5582.	2.9	56
130	Specific Pathogen Detection Using Bioorthogonal Chemistry and Diagnostic Magnetic Resonance. <i>Bioconjugate Chemistry</i> , 2011, 22, 2390-2394.	1.8	59
131	Nanoparticle-Mediated Measurement of Targeted Drug Binding in Cancer Cells. <i>ACS Nano</i> , 2011, 5, 9216-9224.	7.3	21
132	Ubiquitous Detection of Gram-Positive Bacteria with Bioorthogonal Magnetofluorescent Nanoparticles. <i>ACS Nano</i> , 2011, 5, 8834-8841.	7.3	127
133	High-Yielding, Two-Step 18 F Labeling Strategy for 18 F-PARP1 Inhibitors. <i>ChemMedChem</i> , 2011, 6, 424-427.	1.6	73
134	Synthesis and In Vivo Imaging of a 18 F-Labeled PARP1 Inhibitor Using a Chemically Orthogonal Scavenger-Assisted High-Performance Method. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 1922-1925.	7.2	91
135	Bioorthogonal Probes for Polo-Like Kinase 1 Imaging and Quantification. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 9378-9381.	7.2	79
136	Towards Quantitative Catalytic Lignin Depolymerization. <i>Chemistry - A European Journal</i> , 2011, 17, 5939-5948.	1.7	465
137	Accurate measurement of pancreatic islet β -cell mass using a second-generation fluorescent exendin-4 analog. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12815-12820.	3.3	121
138	Bioorthogonal Small-Molecule Ligands for PARP1 Imaging in Living Cells. <i>ChemBioChem</i> , 2010, 11, 2374-2377.	1.3	56
139	η^6 -Arene complexes of ruthenium and osmium with pendant donor functionalities. <i>Journal of Organometallic Chemistry</i> , 2010, 695, 2667-2672.	0.8	21
140	Near-Infrared Fluorescent Probe for Imaging of Pancreatic β Cells. <i>Bioconjugate Chemistry</i> , 2010, 21, 1362-1368.	1.8	46
141	Side chain functionalized η^5 -tetramethyl cyclopentadienyl complexes of Rh and Ir with a pendant primary amine group. <i>Journal of Organometallic Chemistry</i> , 2009, 694, 1934-1937.	0.8	24